pSivida eyes key market after wining Chinese patent:
This article was originally published in Clinica
Australian firm pSivida has gained its first Chinese patent for its drug-delivery product, BrachySil, for primary liver cancer. The Perth-based firm says it is currently in discussions with commercialisation partners for BrachySil in China, which has the highest incidence of primary liver cancer in the world, with 345,800 cases in 2002. It expects to enter into a supply agreement with a local distributor responsible for obtaining regulatory approval, sales and marketing. The Chinese patent - No ZL 99807447.0 - provides protection for silicon implants comprising tissue compatible biodegradable silicon for drug delivery.